The European Commission issued a permit for the sale of drugs, ramdevpir, making it the first drug is allowed at EU level for the treatment COVID-19. About it said on the website of the EC.
The resolution was issued under the accelerated procedure after the recommendations of the European Agency on medicinal products (EMA).
“Data ramdevpir were evaluated in an exceptionally short period of time using the procedure for moving the verification approach used by EMA during emergency situations in public health”, – is spoken in the message.
The EU added that because of the pandemic, the permit was issued within one week upon the recommendation of the EMA, although it usually takes not less than 67 days.
Ramdevpir – the first remedy, since June 25, are allowed to apply in the European Union during coronavirus infection in adults and adolescents from 12 years of age. It was developed by an American biopharmaceutical company, Gilead Sciences, Inc. in 2015. The drug was administered during an outbreak of Ebola in Africa, as well as for the treatment of coronavirus infections SARS and MERS.
Drug ramdevpir included in the Ukrainian Protocol of treatment of coronavirus infection COVID-19, said the Minister of health, Maxim Stepanov on April 19. The health Ministry wants to buy this medicine and take it back to Ukraine through diplomatic channels.
At the end of June, the US bought almost all the us stocks and the future of the party of ramdevpir three months in advance.
Flash coronavirus infection COVID-19 began in December 2019 in the Chinese city of Wuhan. March 11, 2020, the world health organization declared the spread of the coronavirus pandemic.
According to data from the American Johns Hopkins University, aboutbsee number of infected people in the world reached almost 10.4 million, of which almost 5.36 million recovered, and 511 thousand died.